REGULATORY
CSIMC OKs NHI Price Listing of 17 APIs; Peak Sales of 34 Billion Yen Projected for Eliquis
The Central Social Insurance Medical Council (CSIMC), an advisory body to the health minister, at its general assembly on February 13 approved the NHI price listing of 17 active pharmaceutical ingredients (APIs)/25 products, including Bristol-Myers K.K.’s oral anticoagulant Eliquis (apixaban).…
To read the full story
REGULATORY
- Panel to Weigh Orphan Designation for Tecartus on December 22
December 17, 2025
- LDP League Formally Urges Male HPV Shots Under NIP from FY2026
December 17, 2025
- MHLW Drafts Guideline Update, Urges Makers to Factor Distribution Costs into WPPs
December 16, 2025
- MHLW to Add Company-Driven Route to “Specific-Use Drug” Designations
December 16, 2025
- MHLW Council Determines 3 “Drug Loss” Products as High-Need, to Seek Development
December 16, 2025
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…





